Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Relay Therapeutics (RLAY)
NASDAQ:RLAY
Holding RLAY?
Track your performance easily
RLAY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.25 - $12.14
Previous Close$4.71
Volume1.76M
Average Volume (3M)1.91M
Market Cap
$788.37M
Enterprise Value$685.83M
Total Cash (Recent Filing)$152.36M
Total Debt (Recent Filing)$49.81M
Price to Earnings (P/E)―
Beta2.79
Next Earnings
Feb 20, 2025EPS Estimate
-$0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.61
Shares Outstanding167,382,958
10 Day Avg. Volume3,291,445
30 Day Avg. Volume1,905,123
Standard Deviation0.19
R-Squared0.17
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.94
Price to Sales (P/S)78.79
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue68.54
Enterprise Value/Gross Profit26.85
Enterprise Value/Ebitda-2.59
Forecast
1Y Price Target
$19.43Price Target Upside312.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Relay Therapeutics News
PremiumCompany Announcements
Relay Therapeutics Reports Promising Data on RLY-2608
PremiumCompany Announcements
Relay Therapeutics Reports Q3 2024 Results and AdvancesBulls Say, Bears Say
Bulls Say
Clinical EfficacyRelay Therapeutics demonstrated an improvement in efficacy with an increase in overall response rate from 33% to 39% and clinical benefit rate from 57% to 67%.
Financial StrengthRelay ended 3Q24 with $839.6M in cash, which should span several key data catalysts since these resources should be sufficient to provide an operational runway into 2H27.
Strategic PartnershipsRelay Therapeutics announced an exclusive global licensing agreement with Elevar Therapeutics for its FGFR2 inhibitor, lirafugratinib, which includes global development and commercialization rights.
Bears Say
Clinical Data ComparisonPhase 1 data for Scorpion's STX-478 in advanced HR+/HER2- breast cancer appears to be trending better than RLY-2608 at this early stage.
Competitive PressureInvestor anxiety exists surrounding competitor drug STX-478, which may impact RLAY's standing.
Regulatory And Development RisksFailure to obtain regulatory approvals and setbacks in later-stage clinical studies are identified as significant risks.
---
Ownership Overview
3.00% Insiders
18.96% Mutual Funds
51.61% Other Institutional Investors
12.03% Public Companies and
Individual Investors
RLAY FAQ
What was Relay Therapeutics’s price range in the past 12 months?
Relay Therapeutics lowest stock price was $4.25 and its highest was $12.14 in the past 12 months.
What is Relay Therapeutics’s market cap?
Currently, no data Available
When is Relay Therapeutics’s upcoming earnings report date?
Relay Therapeutics’s upcoming earnings report date is Feb 20, 2025 which is in 59 days.
How were Relay Therapeutics’s earnings last quarter?
Relay Therapeutics released its earnings results on Nov 06, 2024. The company reported -$0.63 earnings per share for the quarter, beating the consensus estimate of -$0.772 by $0.142.
Is Relay Therapeutics overvalued?
According to Wall Street analysts Relay Therapeutics’s price is currently Undervalued.
Does Relay Therapeutics pay dividends?
Relay Therapeutics does not currently pay dividends.
What is Relay Therapeutics’s EPS estimate?
Relay Therapeutics’s EPS estimate is -$0.57.
How many shares outstanding does Relay Therapeutics have?
Relay Therapeutics has 167,382,970 shares outstanding.
What happened to Relay Therapeutics’s price movement after its last earnings report?
Relay Therapeutics reported an EPS of -$0.63 in its last earnings report, beating expectations of -$0.772. Following the earnings report the stock price went down -1.76%.
Which hedge fund is a major shareholder of Relay Therapeutics?
Among the largest hedge funds holding Relay Therapeutics’s share is Baker Bros Advisors LP. It holds Relay Therapeutics’s shares valued at 8M.
---
Relay Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.43 (312.53% Upside)
$19.43 (312.53% Upside)
Blogger Sentiment
Bullish
RLAY Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 779.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $57.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 3.0%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.27%
12-Months-Change
Fundamentals
Return on Equity
-42.69%
Trailing 12-Months
Asset Growth
2.55%
Trailing 12-Months
Company Description
Relay Therapeutics
Relay Therapeutics Inc is a precision medicines company focused on enhancing small molecule therapeutic discovery in targeted oncology. Its pipeline products include RLY-1971 and RLY-4008 and among others.
---
RLAY Stock 12 Month Forecast
Average Price Target
$19.43
▲(312.53% Upside)
Technical Analysis
Best Analysts Covering RLAY
1 Year
1 Year Success Rate
1/19 ratings generated profit
1 Year Average Return
-34.96%
assigned a buy rating 19 days ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 5.26% of your transactions generating a profit, with an average return of -34.96% per trade.
---